Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biolexis Shows Positive DIO Model Data for BLX-7006
Details : BLX-7006 is an oral small molecule GLP-1 agonist, which is evaluated to provide potential breakthroughs in the global fight against obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biolexis Unveils Promising Data for Oral Weight Loss Drug BLX-7006 in Studies
Details : BLX-7006 is an oral small molecule GLP-1 agonist, which is evaluated in preclinical studies to provide potential breakthroughs in the global fight against obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biolexis Reports Promising Preclinical Data for Oral Weight Loss Drug BLX-7006
Details : Oral small molecule GLP-1 agonist, BLX-7006, is being investigated in patients with obesity and type-2 diabetes, as a weight loss/management drug.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : BLX-7006
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BLX 0871
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biolexis Advances AMPK Agonists for Weight Loss in Preclinical Development
Details : BLX 0871 is an AMPK activator, which is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : BLX 0871
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Halia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Halia and Biolexis Partner To Develop NLRP3 Neuroinflammation Therapy
Details : The collaboration successfully identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis' MolecuLern™ AI-enabled approach.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 31, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Halia Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : MLX0800
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Clarke Capital
Deal Size : $10.0 million
Deal Type : Series A Financing
Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development
Details : The new funding will advance Biolexis' development pipeline which includes a range of promising metabolic drug candidates, including MLX0800, oral small molecules for the treatment of obesity and type 2 diabetes.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2023
Lead Product(s) : MLX0800
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Clarke Capital
Deal Size : $10.0 million
Deal Type : Series A Financing
Lead Product(s) : MLX7000
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Metabolexis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MLX7000 is a oral small molecules, which is trageted as Glucagon-like peptide-1 receptor, which is investigated for the treatment of weight loss and type 2 diabetic.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : MLX7000
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Metabolexis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Biolexis gains the right to manufacture and commercialize AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa largely covering the low-and-middle-income countries (LMICs).
Product Name : AmbiVax-C
Product Type : Vaccine
Upfront Cash : Undisclosed
March 17, 2022
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration